. Author manuscript; available in PMC: 2017 Apr 15.

Published in final edited form as: Cancer. 2016 Mar 11;122(8):1270–1282. doi: 10.1002/cncr.29906

Table 5.

Effects of the intervention on biological outcomes in patients reporting clinical levels of symptoms at baseline

Biomarker	Baseline		6-months		Effect Size (Phi)
	Intervention (Mean, SD)	Usual Care (Mean, SD)	Intervention (Mean, SD)	Usual Care (Mean, SD)
	n=42	n=39	n=15	n=12
IL-6 pg/ml	197.3 (989)	57.5 (132.3)	35.1 (39.7)	28.7 (27.9)	0.178
IL-1β pg/ml	573.9 (1618)	184.8 (367.7	186.5 (363.5)	243.6 (560.2)	0.353^ˆ
IL-1α pg/ml	575.6 (3233)	149.7 (710)	89.7 (188.2)	33.0 (50.8)	0.194
IL-8 pg/ml	169.1 (225)	217.3 (371)	132.2 (81.4)	75.7 (55.2)	0.153
NK cell number	70.9 (71.6)	75.4 (80.1)	191.8 (77.2)	54.8 (44.3)	0.227^ˆ

Phi=small effect<0.10; medium effect<0.30; large effect<0.50

^ˆ

p<0.10;

p=0.05;

^**

p=0.01;

^***

p<0.001